Provided by Tiger Fintech (Singapore) Pte. Ltd.

iHuman

1.96
+0.12006.52%
Volume:14.15K
Turnover:27.39K
Market Cap:101.95M
PE:7.95
High:1.98
Open:1.89
Low:1.81
Close:1.84
Loading ...

Avadel and nference Announce Publication of Real-World Data on Sodium Oxybate Treatment Patterns in the Journal of Clinical Neuroscience

GlobeNewswire
·
17 Apr

Is Jazz Pharmaceuticals a Top Cannabis Investment for 2025?

Zacks
·
17 Apr

Avadel Pharmaceuticals Provides Update at Needham Virtual Healthcare Conference

GlobeNewswire
·
09 Apr

Harmony Biosciences Holdings, Inc. (HRMY): A Bull Case Theory

Insider Monkey
·
04 Apr

Incannex Healthcare Completes Phase 2 Enrollment in RePOSA Phase 2/3 Trial of IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA)

GlobeNewswire
·
03 Apr

Do Its Financials Have Any Role To Play In Driving iHuman Inc.'s (NYSE:IH) Stock Up Recently?

Simply Wall St.
·
27 Mar

Stock Track | iHuman Stock Plummets 5.79% Following Disappointing Q4 and Full Year 2024 Results

Stock Track
·
25 Mar

Stock Track | iHuman Stock Plummets 5.79% as Q4 Revenue and Profit Decline

Stock Track
·
25 Mar

Ihuman Inc. Announces Fourth Quarter and Fiscal Year 2024 Unaudited Financial Results

THOMSON REUTERS
·
25 Mar

Ihuman Q4 Gross Profit RMB 156.4 Million

THOMSON REUTERS
·
25 Mar

Press Release: iHuman Inc. Announces Fourth Quarter and Fiscal Year 2024 Unaudited Financial Results

Dow Jones
·
25 Mar

CNH Industrial says precision technology helping farmers tackle water scarcity

TIPRANKS
·
24 Mar

Press Release: Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024

Dow Jones
·
24 Mar

HRMY Down 10.8% in Six Months: How Should You Play the Stock?

Zacks
·
20 Mar

Zevra Reports Full Year 2024 and Fourth Quarter Financial Results

GlobeNewswire
·
12 Mar

BUZZ-U.S. STOCKS ON THE MOVE-Willis Lease Finance, CME Group

Reuters
·
11 Mar

Centessa Pharmaceuticals Announces Poster Presentation of Phase 1 Clinical Data for ORX750, a novel orexin receptor 2 (OX2R) agonist, at the American Academy of Neurology (AAN) 2025 Annual Meeting

GlobeNewswire
·
07 Mar

Stock Track | iHuman Stock Soars 6.54% as Lumryz Sales Surge and 2025 Guidance Reaffirmed

Stock Track
·
03 Mar

Avadel Pharmaceuticals Reiterates 2025 Guidance as it Reports Fourth Quarter and Full Year 2024 Financial Results

GlobeNewswire
·
03 Mar

The recent 11% gain must have brightened Top Key Executive Yufeng Chi's week, iHuman Inc.'s (NYSE:IH) most bullish insider

Simply Wall St.
·
28 Feb